Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EBT (2016 - 2025)

Historic EBT for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $47.5 million.

  • Adma Biologics' EBT rose 2929.6% to $47.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.8 million, marking a year-over-year increase of 11235.48%. This contributed to the annual value of $125.7 million for FY2024, which is 54517.87% up from last year.
  • Per Adma Biologics' latest filing, its EBT stood at $47.5 million for Q3 2025, which was up 2929.6% from $40.1 million recorded in Q2 2025.
  • Adma Biologics' 5-year EBT high stood at $47.5 million for Q3 2025, and its period low was -$18.8 million during Q2 2021.
  • Over the past 5 years, Adma Biologics' median EBT value was -$6.8 million (recorded in 2023), while the average stood at $4.7 million.
  • Per our database at Business Quant, Adma Biologics' EBT crashed by 4962.75% in 2023 and then surged by 133270.96% in 2024.
  • Over the past 5 years, Adma Biologics' EBT (Quarter) stood at -$16.5 million in 2021, then grew by 28.55% to -$11.8 million in 2022, then crashed by 49.63% to -$17.6 million in 2023, then soared by 296.73% to $34.7 million in 2024, then surged by 36.88% to $47.5 million in 2025.
  • Its EBT was $47.5 million in Q3 2025, compared to $40.1 million in Q2 2025 and $33.4 million in Q1 2025.